Literature DB >> 15690061

Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expression.

T Pipiya1, H Sauthoff, Y Q Huang, B Chang, J Cheng, S Heitner, S Chen, W N Rom, J G Hay.   

Abstract

Successful cancer therapy using replicating viral vectors relies on the spread of virus from infected to uninfected cells. To date, there has been limited clinical success in the use of replicating adenoviruses. In animal models, established xenograft tumors are rarely eliminated despite the persistence of high viral titers within the tumor. Hypoxia is a prevalent characteristic of solid tumors, whereas adenovirus naturally infects tissues exposed to ambient oxygen concentrations. Here, we report that hypoxia (1% oxygen) reduces adenoviral replication in H1299 and A549 lung cancer cells, BxPC-3 pancreatic cancer cells, LNCaP prostate cancer cells and HCT116 colon cancer cells. However, hypoxia does not reduce cell viability or restrict S-phase entry. Importantly, the production of E1a and fiber proteins under hypoxic conditions was substantially decreased at 24 and 48 h compared to room air controls. In contrast, Northern analysis showed similar levels of E1a mRNA in room air and hypoxic conditions. In conclusion, a level of hypoxia similar to that found within solid tumors reduces the replication of adenoviral vectors by reduction of viral protein expression without a reduction in mRNA levels. To further improve oncolytic therapy using a replicating adenovirus, it is important to understand the mechanism through which hypoxia and the virus interact to control expression of viral and cellular proteins, and consequently to develop means to overcome decreased viral production in hypoxic conditions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15690061     DOI: 10.1038/sj.gt.3302459

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  38 in total

1.  Actin-resistant DNAse I Expression From Oncolytic Adenovirus Enadenotucirev Enhances Its Intratumoral Spread and Reduces Tumor Growth.

Authors:  Alison Tedcastle; Sam Illingworth; Alice Brown; Leonard W Seymour; Kerry D Fisher
Journal:  Mol Ther       Date:  2015-12-28       Impact factor: 11.454

Review 2.  Advances in preclinical investigation of prostate cancer gene therapy.

Authors:  Marxa L Figueiredo; Chinghai Kao; Lily Wu
Journal:  Mol Ther       Date:  2007-04-24       Impact factor: 11.454

Review 3.  Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacy.

Authors:  Drew A Spencer; Jacob S Young; Deepak Kanojia; Julius W Kim; Sean P Polster; Jason P Murphy; Maciej S Lesniak
Journal:  Ther Deliv       Date:  2015

Review 4.  The roles of viruses in brain tumor initiation and oncomodulation.

Authors:  Alexander Kofman; Lucasz Marcinkiewicz; Evan Dupart; Anton Lyshchev; Boris Martynov; Anatolii Ryndin; Elena Kotelevskaya; Jay Brown; David Schiff; Roger Abounader
Journal:  J Neurooncol       Date:  2011-07-01       Impact factor: 4.130

5.  Potent antitumor activity of Oct4 and hypoxia dual-regulated oncolytic adenovirus against bladder cancer.

Authors:  C-S Lu; J-L Hsieh; C-Y Lin; H-W Tsai; B-H Su; G-S Shieh; Y-C Su; C-H Lee; M-Y Chang; C-L Wu; A-L Shiau
Journal:  Gene Ther       Date:  2015-01-15       Impact factor: 5.250

6.  Oncolytic Viruses Engineered to Enforce Leptin Expression Reprogram Tumor-Infiltrating T Cell Metabolism and Promote Tumor Clearance.

Authors:  Dayana B Rivadeneira; Kristin DePeaux; Yiyang Wang; Aditi Kulkarni; Tracy Tabib; Ashley V Menk; Padmavathi Sampath; Robert Lafyatis; Robert L Ferris; Saumendra N Sarkar; Stephen H Thorne; Greg M Delgoffe
Journal:  Immunity       Date:  2019-08-27       Impact factor: 31.745

Review 7.  Impact of tumor microenvironment on oncolytic viral therapy.

Authors:  Jeffrey Wojton; Balveen Kaur
Journal:  Cytokine Growth Factor Rev       Date:  2010 Apr-Jun       Impact factor: 7.638

8.  Hypoxia enhances the replication of oncolytic herpes simplex virus.

Authors:  Manish K Aghi; Ta-Chiang Liu; Samuel Rabkin; Robert L Martuza
Journal:  Mol Ther       Date:  2008-10-28       Impact factor: 11.454

9.  Second-generation HIF-activated oncolytic adenoviruses with improved replication, oncolytic, and antitumor efficacy.

Authors:  T Cherry; S L Longo; Z Tovar-Spinoza; D E Post
Journal:  Gene Ther       Date:  2010-07-22       Impact factor: 5.250

10.  Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumours.

Authors:  C T Hiley; M Yuan; N R Lemoine; Y Wang
Journal:  Gene Ther       Date:  2009-11-05       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.